HCAT
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 1.89 · operating margin -12% — readings disagree
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 59 000 titres (~105 438,90 $ US)
- Insiders
- Kohl Simeon
- Total bought
-
$105,439
Avg buy (VWAP, 90d window) $1.79 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-09-14
- Last synced
-
2026-09-20 09:54:07
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-14 | Kohl Simeon | Buy | 59,000 | $1.79 | $105,439 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-09-18
Despite a moderately compelling insider cluster buy signal from the newly appointed CEO (score 65, confidence 0.7), HCAT's underlying financial health is critically weak, with liquidity and fundamental trend scores of…
The first sentence of the analysis written for HCAT on 2026-09-18 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 33.5% | 45.9% | 44.5% | 48.2% | 48.6% | |
| Ebit Margin | -51.7% | -17.0% | -37.3% | -48.7% | -59.0% | |
| Ebitda Margin | -35.5% | -3.5% | -23.1% | -30.0% | -42.0% | |
| Operating Profit Margin | -11.6% | -22.8% | -42.9% | -50.7% | -59.4% | |
| Pretax Profit Margin | -57.0% | -22.6% | -39.8% | -51.3% | -66.2% | |
| Continuous Operations Profit Margin | -57.2% | -22.7% | -39.9% | -49.7% | -63.3% | |
| Net Profit Margin | -57.2% | -22.7% | -39.9% | -49.7% | -63.3% | |
| Bottom Line Profit Margin | -57.2% | -22.7% | -39.9% | -49.7% | -63.3% | |
| Current Ratio | 1.890 | 1.429 | 4.419 | 5.185 | 5.464 | |
| Quick Ratio | 1.890 | 1.429 | 4.419 | 5.185 | 5.464 | |
| Solvency Ratio | -0.496 | -0.057 | -0.227 | -0.262 | -0.362 | |
| Cash Ratio | 0.567 | 0.766 | 1.194 | 1.410 | 2.077 | |
| Price To Earnings Ratio | -0.937 | -6.148 | -4.431 | -4.152 | -12.266 | |
| Price To Earnings Growth Ratio | -0.008 | 0.137 | 0.241 | 0.200 | -1.115 | |
| Forward Price To Earnings Growth Ratio | -0.008 | 0.137 | 0.241 | 0.200 | -1.115 | |
| Price To Earnings Diluted Ratio | -0.937 | -6.148 | -4.431 | -4.185 | -12.266 | |
| Price To Earnings Diluted Growth Ratio | -0.008 | 0.137 | 0.250 | 0.196 | -1.115 | |
| Price To Book Ratio | 0.680 | 1.165 | 1.424 | 1.344 | 3.604 | |
| Price To Sales Ratio | 0.537 | 1.388 | 1.765 | 2.067 | 7.778 | |
| Price To Free Cash Flow Ratio | -704.858 | -231.380 | -11.024 | -10.839 | -45.245 | |
| Price To Operating Cash Flow Ratio | 228.525 | 29.226 | -15.793 | -16.191 | -81.380 | |
| Debt To Assets Ratio | 0.341 | 0.468 | 0.355 | 0.330 | 0.246 | |
| Debt To Equity Ratio | 0.697 | 1.101 | 0.679 | 0.583 | 0.392 | |
| Debt To Capital Ratio | 0.411 | 0.524 | 0.404 | 0.368 | 0.282 | |
| Long Term Debt To Capital Ratio | 0.382 | 0.293 | 0.383 | 0.348 | 0.257 | |
| Financial Leverage Ratio | 2.045 | 2.352 | 1.913 | 1.770 | 1.594 | |
| Working Capital Turnover Ratio | 2.835 | 1.381 | 0.911 | 0.726 | 0.736 | |
| Operating Cash Flow Ratio | 0.008 | 0.045 | -0.372 | -0.427 | -0.248 | |
| Operating Cash Flow Sales Ratio | 0.002 | 0.047 | -0.112 | -0.128 | -0.096 | |
| Free Cash Flow Operating Cash Flow Ratio | -0.324 | -0.126 | 1.433 | 1.494 | 1.799 | |
| Debt Service Coverage Ratio | -6.160 | -0.044 | -9.419 | -10.863 | -5.475 | |
| Interest Coverage Ratio | -2.201 | -4.086 | -17.414 | -19.340 | -8.297 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.449 | 0.063 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.004 | 0.036 | -0.133 | -0.142 | -0.113 | |
| Capital Expenditure Coverage Ratio | 0.755 | 0.888 | -2.312 | -2.025 | -1.252 | |
| Dividend Paid And Capex Coverage Ratio | 0.755 | 0.888 | -2.312 | -2.025 | -1.252 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.605 | -54.274 | -9.742 | -8.475 | -18.618 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 33.5% | ▼-12.4% | ▼-10.7% |
| Ebit Margin | -51.7% | ▼-34.7% | ▼-8.9% |
| Ebitda Margin | -35.5% | ▼-32.0% | ▼-8.7% |
| Operating Profit Margin | -11.6% | ▲11.2% | ▲25.9% |
| Pretax Profit Margin | -57.0% | ▼-34.4% | ▼-9.6% |
| Continuous Operations Profit Margin | -57.2% | ▼-34.5% | ▼-10.6% |
| Net Profit Margin | -57.2% | ▼-34.5% | ▼-10.6% |
| Bottom Line Profit Margin | -57.2% | ▼-34.5% | ▼-10.6% |
| Current Ratio | 1.890 | ▲0.461 | ▼-1.787 |
| Quick Ratio | 1.890 | ▲0.461 | ▼-1.787 |
| Solvency Ratio | -0.496 | ▼-0.439 | ▼-0.215 |
| Cash Ratio | 0.567 | ▼-0.199 | ▼-0.635 |
| Price To Earnings Ratio | -0.937 | ▲5.211 | ▲4.650 |
| Price To Earnings Growth Ratio | -0.008 | ▼-0.144 | ▲0.101 |
| Forward Price To Earnings Growth Ratio | -0.008 | ▼-0.144 | ▲0.101 |
| Price To Earnings Diluted Ratio | -0.937 | ▲5.211 | ▲4.656 |
| Price To Earnings Diluted Growth Ratio | -0.008 | ▼-0.144 | ▲0.100 |
| Price To Book Ratio | 0.680 | ▼-0.485 | ▼-0.964 |
| Price To Sales Ratio | 0.537 | ▼-0.851 | ▼-2.170 |
| Price To Free Cash Flow Ratio | -704.858 | ▼-473.478 | ▼-504.189 |
| Price To Operating Cash Flow Ratio | 228.524 | ▲199.298 | ▲199.647 |
| Debt To Assets Ratio | 0.341 | ▼-0.128 | ▼-0.007 |
| Debt To Equity Ratio | 0.697 | ▼-0.405 | ▲0.006 |
| Debt To Capital Ratio | 0.411 | ▼-0.114 | ▲0.013 |
| Long Term Debt To Capital Ratio | 0.382 | ▲0.089 | ▲0.049 |
| Financial Leverage Ratio | 2.045 | ▼-0.307 | ▲0.110 |
| Working Capital Turnover Ratio | 2.834 | ▲1.454 | ▲1.517 |
| Operating Cash Flow Ratio | 0.008 | ▼-0.036 | ▲0.207 |
| Operating Cash Flow Sales Ratio | 0.002 | ▼-0.045 | ▲0.059 |
| Free Cash Flow Operating Cash Flow Ratio | -0.324 | ▼-0.198 | ▼-1.179 |
| Debt Service Coverage Ratio | -6.160 | ▼-6.116 | ▲0.232 |
| Interest Coverage Ratio | -2.201 | ▲1.885 | ▲8.067 |
| Short Term Operating Cash Flow Coverage Ratio | 0.449 | ▲0.386 | ▲0.347 |
| Operating Cash Flow Coverage Ratio | 0.004 | ▼-0.032 | ▲0.074 |
| Capital Expenditure Coverage Ratio | 0.755 | ▼-0.133 | ▲1.544 |
| Dividend Paid And Capex Coverage Ratio | 0.755 | ▼-0.133 | ▲1.544 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.605 | ▲51.669 | ▲16.138 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $167.1M | $425.5M | $522.4M | $571.1M | $1.88B | |
| Enterprise value | $287.5M | $578.1M | $665.2M | $702.7M | $1.89B | |
| EV / Sales | 0.92x | 1.89x | 2.25x | 2.54x | 7.83x | |
| EV / Op. cash flow | 393.26x | 39.71x | -20.11x | -19.92x | -81.87x | |
| EV / Free cash flow | -1212.98x | -314.37x | -14.04x | -13.34x | -45.52x | |
| EV / EBITDA | -2.60x | -54.27x | -9.74x | -8.47x | -18.62x | |
| Net debt / EBITDA | -1.09x | -14.33x | -2.09x | -1.59x | -0.11x | |
| Current ratio | 1.89x | 1.43x | 4.42x | 5.18x | 5.46x | |
| Income quality | -0.00x | -0.21x | 0.28x | 0.26x | 0.15x | |
| Graham net-net | -$2 | -$1 | $0 | $1 | $4 | |
| Tax burden | 100.4% | 100.5% | 100.3% | 97.0% | 95.7% | |
| Interest burden | 110.2% | 132.8% | 106.6% | 105.4% | 112.1% | |
| Working capital | $79.7M | $139.8M | $304.4M | $345.3M | $415.3M | |
| Invested capital | $407.0M | $527.1M | $608.0M | $666.0M | $734.5M | |
| Return on assets | -35.4% | -8.1% | -16.8% | -18.3% | -18.4% | |
| Operating ROA | -5.3% | -8.9% | -17.5% | -17.7% | -20.4% | |
| Return on tangible assets | -82.4% | -13.5% | -27.0% | -29.0% | -27.5% | |
| Return on equity | -72.4% | -19.0% | -32.2% | -32.3% | -29.3% | |
| Return on invested capital | -8.6% | -9.1% | -20.6% | -20.2% | -18.5% | |
| Return on capital employed | -8.7% | -13.1% | -20.7% | -20.9% | -19.4% | |
| Earnings yield | -106.5% | -16.3% | -22.6% | -24.1% | -8.1% | |
| Free cash flow yield | -0.1% | -0.4% | -9.1% | -9.2% | -2.2% | |
| Capex / Op. cash flow | 132.4% | 112.6% | -43.3% | -49.4% | -79.9% | |
| Capex / Depreciation | 1.9% | 39.6% | 33.9% | 36.1% | 49.2% | |
| Capex / Sales | 0.3% | 5.3% | 4.8% | 6.3% | 7.6% | |
| SG&A / Sales | 32.8% | 36.3% | 48.6% | 54.0% | 66.5% | |
| R&D / Sales | 16.0% | 18.9% | 24.5% | 27.4% | 25.9% | |
| Stock comp / Sales | 8.7% | 13.1% | 18.8% | 26.1% | 26.9% | |
| Intangibles / Total assets | 57.0% | 40.3% | 37.6% | 37.0% | 33.0% | |
| Days sales outstanding | 69d | 68d | 74d | 63d | 74d | |
| Days payables outstanding | 17d | 25d | 15d | 11d | 14d | |
| Operating cycle | 69d | 68d | 74d | 63d | 74d | |
| Cash conversion cycle | 53d | 43d | 60d | 52d | 60d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-60.7%EV / Sales ▼-51.0%EV / EBITDA ▲+95.2%EV / Op. cash flow ▲+353.554Earnings yield ▼-0.902
Profitability
Return on equity ▼-0.534Return on assets ▼-0.273Return on invested capital ▲+0.005Return on capital employed ▲+0.044Operating ROA ▲+0.036Income quality ▲+0.205Tax burden ▼-0.001
Efficiency
Days sales outstanding ▲+1.287Days payables outstanding ▼-8.659Operating cycle ▲+1.287Cash conversion cycle ▲+9.946Capex / Sales ▼-0.050R&D / Sales ▼-0.029
Balance-sheet strength
Current ratio ▲+0.461Net debt / EBITDA ▲+13.237Working capital ▼-60066000.000Invested capital ▼-120100000.000Intangibles / Total assets ▲+0.168
Change over 5 years
Valuation
Market cap ▼-91.1%EV / Sales ▼-88.2%EV / EBITDA ▲+86.0%EV / Op. cash flow ▲+475.135Earnings yield ▼-0.984
Profitability
Return on equity ▼-0.431Return on assets ▼-0.170Return on invested capital ▲+0.099Return on capital employed ▲+0.107Operating ROA ▲+0.151Income quality ▼-0.155Tax burden ▲+0.047
Efficiency
Days sales outstanding ▼-4.263Days payables outstanding ▲+2.735Operating cycle ▼-4.263Cash conversion cycle ▼-6.998Capex / Sales ▼-0.073R&D / Sales ▼-0.099
Balance-sheet strength
Current ratio ▼-3.573Net debt / EBITDA ▼-0.979Working capital ▼-335606000.000Invested capital ▼-327586000.000Intangibles / Total assets ▲+0.240
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-14 Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SALT LAKE CITY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that on September 14, 2026, the Compensation Committee of the Company''s Board of Directors granted 2,747,385 restricted stock units (the “RSUs”) to Simeon Kohl under the Health Catalyst, Inc. 2026 Employment Inducement Incentive Plan (the “Inducement Plan”) in connection with Mr. Kohl''s previously announced appointment as Chief Executive Officer and President of the Company effective on September 14, 2026. The awards were granted as inducement material to Mr. Kohl''s entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-09-14 Health Catalyst Strengthens Its Board with the Appointment of Tami Reller Reller Joins Health Catalyst as it Enters Its Next Phase of Growth SALT LAKE CITY, Sept. 14, 2026 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst", NASDAQ: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Tami Reller has been appointed to its board of directors (Board), effective October 1, 2026.
- 2026-09-08 Health Catalyst Appoints Simeon Kohl as Chief Executive Officer and President SALT LAKE CITY, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Simeon Kohl has been appointed Chief Executive Officer (CEO) and President and a member of the Company''s Board of Directors, effective September 14, 2026.
- 2026-09-02 Hsbc Holdings PLC Invests $809,000 in Health Catalyst, Inc. $HCAT Hsbc Holdings PLC bought a new stake in Health Catalyst, Inc. (NASDAQ: HCAT) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 408,634 shares of the company''s stock, valued at approximately $809,000. Hsbc Holdings PLC owned approximately 0.54% of Health Catalyst
- 2026-08-31 Health Catalyst to Participate in Upcoming Investor Conference SALT LAKE CITY, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that members of senior management will participate in the 2026 Wells Fargo Healthcare Conference, taking place in Boston, on Wednesday, September 9, 2026 and Thursday, September 10, 2026.
- 2026-08-24 Critical Survey: Aclarion (NASDAQ:ACONW) and Health Catalyst (NASDAQ:HCAT) Health Catalyst (NASDAQ: HCAT - Get Free Report) and Aclarion (NASDAQ: ACONW - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations. Insider and Institutional Ownership 85.0% of Health Catalyst shares
- 2026-08-12 Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Rating of “Hold” from Analysts Health Catalyst, Inc. (NASDAQ: HCAT - Get Free Report) has earned an average rating of "Hold" from the thirteen analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and four have assigned a buy recommendation to the company. The
- 2026-08-12 Health Catalyst (NASDAQ:HCAT) and Lynx Global Digital Finance (OTCMKTS:CNONF) Head-To-Head Review Health Catalyst (NASDAQ: HCAT - Get Free Report) and Lynx Global Digital Finance (OTCMKTS:CNONF - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership. Earnings and Valuation This table compares
- 2026-08-06 Health Catalyst Q2 Earnings Call Highlights Health Catalyst NASDAQ: HCAT reported second-quarter 2026 revenue above the high end of its guidance range and adjusted EBITDA at the high end of its outlook, while outlining a strategic shift following the July 31 divestiture of its Vitalware and Med-Metrix businesses.
- 2026-08-06 Health Catalyst, Inc. (HCAT) Q2 2026 Earnings Call Transcript Health Catalyst, Inc. (HCAT) Q2 2026 Earnings Call Transcript